نتایج جستجو برای: pneumococcal vaccine

تعداد نتایج: 116043  

Journal: :PharmacoEconomics 2000
D De Graeve G Lombaert H Goossens

OBJECTIVE To analyse the direct medical costs and effectiveness of vaccinating adults aged between 18 and 64 years and elderly persons > or = 65 years of age with the 23-valent pneumococcal polysaccharide vaccine. DESIGN AND SETTING This was a decision-analytic modelling study from the societal perspective in Belgium. The analysis compared 'vaccination' with 'no vaccination and treatment'. ...

2017
Jennifer E. Cornick Özlem Tastan Bishop Feyruz Yalcin Anmol M. Kiran Benjamin Kumwenda Chrispin Chaguza Shanil Govindpershad Sani Ousmane Madikay Senghore Mignon du Plessis Gerd Pluschke Chinelo Ebruke Lesley McGee Beutel Sigaùque Jean-Marc Collard Stephen D. Bentley Aras Kadioglu Martin Antonio Anne von Gottberg Neil French Keith P. Klugman Robert S. Heyderman Mark Alderson Dean B. Everett

Serotype 1 is one of the most common causes of pneumococcal disease worldwide. Pneumococcal protein vaccines are currently being developed as an alternate intervention strategy to pneumococcal conjugate vaccines. Pre-requisites for an efficacious pneumococcal protein vaccine are universal presence and minimal variation of the target antigen in the pneumococcal population, and the capability to ...

2015
Kimiko Ubukata Naoko Chiba Shigeo Hanada Miyuki Morozumi Takeaki Wajima Michi Shouji Satoshi Iwata

After 7-valent pneumococcal conjugate vaccine (PCV) for children was introduced in Japan in November 2010, we examined changes in Streptococcus pneumoniae serotypes and in genetic antimicrobial drug resistance of isolates from adults with invasive pneumococcal diseases. During April 2010-March 2013, a total of 715 isolates were collected from adults with invasive pneumococcal diseases. Seven-va...

2017
Esra Kürüm Joshua L. Warren Cynthia Schuck-Paim Roger Lustig Joseph A. Lewnard Rodrigo Fuentes Christian A. W. Bruhn Robert J. Taylor Lone Simonsen Daniel M. Weinberger

BACKGROUND Pneumococcal conjugate vaccines (PCVs) prevent invasive pneumococcal disease and pneumonia. However, some low-and middle-income countries have yet to introduce PCV into their immunization programs due, in part, to lack of certainty about the potential impact. Assessing PCV benefits is challenging because specific data on pneumococcal disease are often lacking, and it can be difficult...

Journal: :Journal of clinical microbiology 2007
Alan Basset Krzysztof Trzcinski Christina Hermos Katherine L O'Brien Raymond Reid Mathuram Santosham Alexander J McAdam Marc Lipsitch Richard Malley

The recent discovery of a mobile genetic element encoding a pilus-like structure in Streptococcus pneumoniae and the demonstration of a role for the pilus in virulence in mice have led to the proposal of the use of the pilus as a candidate pneumococcal vaccine. We examined the frequency of occurrence of the pneumococcal pilus, as determined by the presence of the rrgC gene, and analyzed its ass...

Journal: :Journal of clinical microbiology 2008
Chinwendu Onwubiko Edwin Swiatlo Larry S McDaniel

Human immunodeficiency virus (HIV)-infected patients have an increased rate of pneumococcal infections. Within the HIV-infected population, patients with low CD4(+) cell counts have a higher rate of pneumococcal infection. The purpose of our study was to determine pneumococcal carriage and to examine the serotypes carried by HIV-infected patients after the introduction of the conjugate vaccine....

Journal: :The new microbiologica 2009
Giuseppe Miragliotta Adriana Mosca Raffaele Del Prete Rosella De Nittis Raffaele Antonetti Anna Di Taranto

Pneumococcal meningitis is still today a life threatening disease among children under-5 worldwide. Although the heptavalent vaccine has demonstrated its ability to reduce the incidence of pneumococcal disease its efficacy is limited due to the restricted number of serotypes included. We report a case of a child with a Streptococcus pneumoniae meningitis despite the use of heptavalent conjugate...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007
Matthew R Moore Katherine O'Brien J Pekka Nuorti Thomas Hennessy

1. Barricarte A, Castilla J, Gil-Setas A, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis 2007; 44:1436–41. 2. Grimes DA, Schutlz KF. Bias and causal associations in observational research. Lancet 2002; 359:248–52. 3. Bland JM, Altman DG. Matching. BMJ 1994; 309:1128. 4. Barricarte A, Gil-Setas A, Torroba A, et al. Inva...

2015
As’ad E. Bhorat Shabir A. Madhi France Laudat Vani Sundaraiyer Alejandra Gurtman Kathrin U. Jansen Daniel A. Scott Emilio A. Emini William C. Gruber Beate Schmoele-Thoma

OBJECTIVE Immunocompromised individuals are at an increased risk of pneumococcal disease. Vaccination is recommended as an important strategy to reduce risk of pneumococcal disease in HIV-infected individuals. This study evaluated the safety and immunogenicity of three 13-valent pneumococcal conjugate vaccine (PCV13) doses followed by one dose of 23-valent pneumococcal polysaccharide vaccine (P...

2011
Bruce Y. Lee Tina-Marie Assi Korngamon Rookkapan Angela R. Wateska Jayant Rajgopal Vorasith Sornsrivichai Sheng-I Chen Shawn T. Brown Joel Welling Bryan A. Norman Diana L. Connor Rachel R. Bailey Anirban Jana Willem G. Van Panhuis Donald S. Burke

Although the substantial burdens of rotavirus and pneumococcal disease have motivated many countries to consider introducing the rotavirus vaccine (RV) and heptavalent pneumococcal conjugate vaccine (PCV-7) to their National Immunization Programs (EPIs), these new vaccines could affect the countries' vaccine supply chains (i.e., the series of steps required to get a vaccine from their manufactu...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید